BFM
FOLD

Boothbay Fund Management’s Amicus Therapeutics FOLD Stock Holding History

Boothbay Fund Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-214,500
Closed -$2.05M – 1976
2021
Q3 		$2.05M Buy
+214,500
New +$2.19M 0.06% 437

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Boothbay Fund Management's FOLD Position: Q1 2026 in Review

Boothbay Fund Management reduced its Amicus Therapeutics (FOLD) stake by 88% in Q1 2026, selling an estimated $2.94M and leaving 28,472 shares worth $412K. The position accounts for 0.01% of the portfolio, ranked #1447.

Boothbay Fund Management first reported a position in FOLD in Q1 2021 and has held it in 8 quarters since. The position peaked at $3.33M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Boothbay Fund Management held 28,472 shares of Amicus Therapeutics worth $412K as of Q1 2026.
  • Boothbay Fund Management sold 205,185 Amicus Therapeutics shares in Q1 2026, an estimated $2.94M.
  • Amicus Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1447 holding.
  • Boothbay Fund Management first reported a position in Amicus Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • Boothbay Fund Management's Amicus Therapeutics position peaked at $3.33M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.